Genetic Technologies unveils major cancer risk Test at California event
Published: 11:42 31 May 2024 AEST
Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) CEO Simon Morriss is back with Proactive after the company launched an assessment to aid in the detection of two types of cancer. The genomic-based biotech has launched a comprehensive risk assessment test, targeting all women at risk of developing breast and ovarian cancer. The innovative assessment, available to women over 30, evaluates cancer risk from hereditary disease, including common gene mutations and sporadic conditions. The test was introduced at the inaugural Know Your Risk event in California, USA, emphasising the role of genomics in women's health. Co-hosted by Dr Kristi Funk and Krystal Barter, the event featured notable panellists like Dr Carolynn Young, Andrea Hans, Allyn Rose Oertel and Matthew Zachary. In short, Morriss says the test offers clinicians a complete understanding of patients’ risk profiles for these cancers. Retrospective data indicates that 5% to 10% of breast and ovarian cancers are caused by gene mutations, with the remainder due to sporadic conditions. This represents a substantial market opportunity for Genetic Technologies' geneType platform, as approximately one in eight women in the US will develop breast cancer, equating to around 310,000 annual cases. Ovarian cancer, although less common, results in 19,600 diagnosed cases and 12,700 deaths annually in the US.
